---
document_datetime: 2025-12-29 11:34:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/jubbonti.html
document_name: jubbonti.html
version: success
processing_time: 0.1212404
conversion_datetime: 2025-12-29 23:55:22.680505
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Jubbonti

[RSS](/en/individual-human-medicine.xml/240139)

##### Authorised

This medicine is authorised for use in the European Union

denosumab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Jubbonti](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79388)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Jubbonti is a medicine used to treat the following conditions:

- osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause, Jubbonti reduces the risk of fractures in the spine and elsewhere in the body, including in the hip;
- bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Jubbonti reduces the risk of fractures in the spine;
- bone loss in adults at increased risk of fractures who are treated long term with corticosteroid medicines given by mouth or injection.

Jubbonti is a biological medicine and contains the active substance denosumab. It is a 'biosimilar medicine'; this means that Jubbonti is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Jubbonti is Prolia. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines) .

Expand section

Collapse section

## How is Jubbonti used?

Jubbonti can only be obtained with a prescription. It is available in prefilled syringes. The medicine is given once every 6 months as an injection under the skin in the thigh, belly or back of the arm. During treatment with Jubbonti, the doctor should ensure that the patient is taking calcium and vitamin D supplements. Jubbonti can be given by someone who has been trained to give the injections.

For more information about using Jubbonti, see the package leaflet or contact your doctor or pharmacist.

## How does Jubbonti work?

The active substance in Jubbonti, denosumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a protein in the body called RANKL. RANKL is involved in activating osteoclasts, the cells in the body that are involved in breaking down bone tissue. By attaching to and blocking RANKL, denosumab reduces the formation and activity of the osteoclasts. This reduces the loss of bone and maintains bone strength, making fractures less likely to happen.

## What benefits of Jubbonti have been shown in studies? Laboratory studies

Laboratory studies comparing Jubbonti with the reference medicine, Prolia, have shown that the active substance in Jubbonti is highly similar to that in Prolia in terms of structure, purity and biological activity. A study has also shown that giving Jubbonti produces similar levels of the active substance in the body to giving Prolia.

In addition, a study involving 463 women with osteoporosis who have been through the menopause showed that Jubbonti is as effective as Prolia at increasing bone mineral density (a measure of how strong the bones are) in the spine. After a year of treatment, bone mineral density increased by around 5% in both women who received Jubbonti and those who received Prolia.

Because Jubbonti is a biosimilar medicine, the studies on the effectiveness and safety of denosumab carried out with Prolia do not all need to be repeated for Jubbonti.

## What are the risks associated with Jubbonti?

The safety of Jubbonti has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine, Prolia.

For the complete list of side effects and restrictions with Jubbonti, see the package leaflet.

The most common side effects with Jubbonti (which may affect more than 1 in 10 people) include pain in the arms or legs, and bone and muscle pain. Cellulitis (inflammation of deep skin tissue) can occur in up to 1 in 100 people. Hypocalcaemia (low blood calcium), hypersensitivity (allergy), osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) and unusual fractures of the thigh were seen in up to 1 in 1000 people.

Jubbonti must not be used in people with hypocalcaemia.

## Why is Jubbonti authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Jubbonti has a highly similar structure, purity and biological activity to Prolia and is distributed in the body in the same way. In addition, a study has shown that Jubbonti and Prolia are equivalent in terms of safety and effectiveness in women with osteoporosis who have been through the menopause.

All these data were considered sufficient to conclude that Jubbonti will have the same effects as Prolia in its authorised uses. Therefore, the Agency's view was that, as for Prolia, the benefits of Jubbonti outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Jubbonti?

The company that markets Jubbonti will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jubbonti have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Jubbonti are continuously monitored. Suspected side effects reported with Jubbonti are carefully evaluated and any necessary action taken to protect patients.

## Other information about Jubbonti

Jubbonti received a marketing authorisation valid throughout the EU on 16 May 2024.

Jubbonti : EPAR - Medicine overview

Reference Number: EMA/134282/2024

English (EN) (136.09 KB - PDF)

**First published:** 06/06/2024

[View](/en/documents/overview/jubbonti-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-312)

български (BG) (160.91 KB - PDF)

**First published:**

06/06/2024

[View](/bg/documents/overview/jubbonti-epar-medicine-overview_bg.pdf)

español (ES) (135.6 KB - PDF)

**First published:**

06/06/2024

[View](/es/documents/overview/jubbonti-epar-medicine-overview_es.pdf)

čeština (CS) (157.77 KB - PDF)

**First published:**

06/06/2024

[View](/cs/documents/overview/jubbonti-epar-medicine-overview_cs.pdf)

dansk (DA) (134.01 KB - PDF)

**First published:**

06/06/2024

[View](/da/documents/overview/jubbonti-epar-medicine-overview_da.pdf)

Deutsch (DE) (138.3 KB - PDF)

**First published:**

06/06/2024

[View](/de/documents/overview/jubbonti-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.51 KB - PDF)

**First published:**

06/06/2024

[View](/et/documents/overview/jubbonti-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.66 KB - PDF)

**First published:**

06/06/2024

[View](/el/documents/overview/jubbonti-epar-medicine-overview_el.pdf)

français (FR) (136.5 KB - PDF)

**First published:**

06/06/2024

[View](/fr/documents/overview/jubbonti-epar-medicine-overview_fr.pdf)

hrvatski (HR) (156.87 KB - PDF)

**First published:**

06/06/2024

[View](/hr/documents/overview/jubbonti-epar-medicine-overview_hr.pdf)

italiano (IT) (134.06 KB - PDF)

**First published:**

06/06/2024

[View](/it/documents/overview/jubbonti-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (165.98 KB - PDF)

**First published:**

06/06/2024

[View](/lv/documents/overview/jubbonti-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (157.05 KB - PDF)

**First published:**

06/06/2024

[View](/lt/documents/overview/jubbonti-epar-medicine-overview_lt.pdf)

magyar (HU) (158.57 KB - PDF)

**First published:**

06/06/2024

[View](/hu/documents/overview/jubbonti-epar-medicine-overview_hu.pdf)

Malti (MT) (160.02 KB - PDF)

**First published:**

06/06/2024

[View](/mt/documents/overview/jubbonti-epar-medicine-overview_mt.pdf)

Nederlands (NL) (135.54 KB - PDF)

**First published:**

06/06/2024

[View](/nl/documents/overview/jubbonti-epar-medicine-overview_nl.pdf)

polski (PL) (158.62 KB - PDF)

**First published:**

06/06/2024

[View](/pl/documents/overview/jubbonti-epar-medicine-overview_pl.pdf)

português (PT) (136.67 KB - PDF)

**First published:**

06/06/2024

[View](/pt/documents/overview/jubbonti-epar-medicine-overview_pt.pdf)

română (RO) (155.17 KB - PDF)

**First published:**

06/06/2024

[View](/ro/documents/overview/jubbonti-epar-medicine-overview_ro.pdf)

slovenčina (SK) (158.7 KB - PDF)

**First published:**

06/06/2024

[View](/sk/documents/overview/jubbonti-epar-medicine-overview_sk.pdf)

slovenščina (SL) (154.78 KB - PDF)

**First published:**

06/06/2024

[View](/sl/documents/overview/jubbonti-epar-medicine-overview_sl.pdf)

Suomi (FI) (132.7 KB - PDF)

**First published:**

06/06/2024

[View](/fi/documents/overview/jubbonti-epar-medicine-overview_fi.pdf)

svenska (SV) (133.75 KB - PDF)

**First published:**

06/06/2024

[View](/sv/documents/overview/jubbonti-epar-medicine-overview_sv.pdf)

Jubbonti : EPAR - Risk management plan

English (EN) (591.29 KB - PDF)

**First published:** 06/06/2024

[View](/en/documents/rmp/jubbonti-epar-risk-management-plan_en.pdf)

## Product information

Jubbonti : EPAR - Product information

English (EN) (3.17 MB - PDF)

**First published:** 06/06/2024

**Last updated:** 27/11/2025

[View](/en/documents/product-information/jubbonti-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-79)

български (BG) (3.73 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/bg/documents/product-information/jubbonti-epar-product-information_bg.pdf)

español (ES) (3.69 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/es/documents/product-information/jubbonti-epar-product-information_es.pdf)

čeština (CS) (3.81 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/cs/documents/product-information/jubbonti-epar-product-information_cs.pdf)

dansk (DA) (3.67 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/da/documents/product-information/jubbonti-epar-product-information_da.pdf)

Deutsch (DE) (4.25 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/de/documents/product-information/jubbonti-epar-product-information_de.pdf)

eesti keel (ET) (3.62 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/et/documents/product-information/jubbonti-epar-product-information_et.pdf)

ελληνικά (EL) (3.77 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/el/documents/product-information/jubbonti-epar-product-information_el.pdf)

français (FR) (3.77 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/fr/documents/product-information/jubbonti-epar-product-information_fr.pdf)

hrvatski (HR) (4.16 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/hr/documents/product-information/jubbonti-epar-product-information_hr.pdf)

íslenska (IS) (3.61 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/is/documents/product-information/jubbonti-epar-product-information_is.pdf)

italiano (IT) (3.82 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/it/documents/product-information/jubbonti-epar-product-information_it.pdf)

latviešu valoda (LV) (3.65 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/lv/documents/product-information/jubbonti-epar-product-information_lv.pdf)

lietuvių kalba (LT) (3.69 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/lt/documents/product-information/jubbonti-epar-product-information_lt.pdf)

magyar (HU) (3.77 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/hu/documents/product-information/jubbonti-epar-product-information_hu.pdf)

Malti (MT) (4.53 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/mt/documents/product-information/jubbonti-epar-product-information_mt.pdf)

Nederlands (NL) (3.68 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/nl/documents/product-information/jubbonti-epar-product-information_nl.pdf)

norsk (NO) (3.66 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/no/documents/product-information/jubbonti-epar-product-information_no.pdf)

polski (PL) (3.71 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/pl/documents/product-information/jubbonti-epar-product-information_pl.pdf)

português (PT) (3.68 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/pt/documents/product-information/jubbonti-epar-product-information_pt.pdf)

română (RO) (3.83 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/ro/documents/product-information/jubbonti-epar-product-information_ro.pdf)

slovenčina (SK) (4.09 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/sk/documents/product-information/jubbonti-epar-product-information_sk.pdf)

slovenščina (SL) (3.75 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/sl/documents/product-information/jubbonti-epar-product-information_sl.pdf)

Suomi (FI) (3.62 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/fi/documents/product-information/jubbonti-epar-product-information_fi.pdf)

svenska (SV) (3.66 MB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/sv/documents/product-information/jubbonti-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000293149 27/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Jubbonti : EPAR - All authorised presentations

English (EN) (32.59 KB - PDF)

**First published:** 06/06/2024

**Last updated:** 27/11/2025

[View](/en/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-692)

български (BG) (559.96 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/bg/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_bg.pdf)

español (ES) (559.78 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/es/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_es.pdf)

čeština (CS) (559.68 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/cs/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (559.7 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/da/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (559.62 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/de/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (559.53 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/et/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (559.74 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/el/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_el.pdf)

français (FR) (559.71 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/fr/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (559.68 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/hr/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (559.58 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/is/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_is.pdf)

italiano (IT) (559.74 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/it/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (559.67 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/lv/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (559.63 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/lt/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (559.77 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/hu/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (559.97 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/mt/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (559.67 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/nl/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (559.65 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/no/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_no.pdf)

polski (PL) (559.79 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/pl/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_pl.pdf)

português (PT) (559.74 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/pt/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_pt.pdf)

română (RO) (559.7 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/ro/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (559.64 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/sk/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (559.76 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/sl/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (559.52 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/fi/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (559.55 KB - PDF)

**First published:**

06/06/2024

**Last updated:**

27/11/2025

[View](/sv/documents/all-authorised-presentations/jubbonti-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Jubbonti Active substance denosumab International non-proprietary name (INN) or common name denosumab Therapeutic area (MeSH)

- Osteoporosis
- Osteoporosis, Postmenopausal
- Bone Resorption

Anatomical therapeutic chemical (ATC) code M05BX04

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures. Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures. Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

## Authorisation details

EMA product number EMEA/H/C/005964

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Sandoz GmbH

Biochemiestr. 10

Opinion adopted 21/03/2024 Marketing authorisation issued 16/05/2024 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Jubbonti : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.04 KB - PDF)

**First published:** 27/11/2025

[View](/en/documents/procedural-steps-after/jubbonti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Jubbonti : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (150.49 KB - PDF)

**First published:** 08/01/2025

**Last updated:** 27/11/2025

[View](/en/documents/procedural-steps-after/jubbonti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Jubbonti : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/305951/2025

English (EN) (137.75 KB - PDF)

**First published:** 19/09/2025

[View](/en/documents/scientific-conclusion/jubbonti-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Jubbonti : EPAR - Public assessment report

Adopted

Reference Number: EMA/169039/2024

English (EN) (3.83 MB - PDF)

**First published:** 06/06/2024

[View](/en/documents/assessment-report/jubbonti-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Jubbonti

Adopted

Reference Number: EMA/99825/2024

English (EN) (144.29 KB - PDF)

**First published:** 22/03/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-jubbonti_en.pdf)

#### News on Jubbonti

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-march-2024) 22/03/2024

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Jubbonti : EPAR - Product information - tracked changes

English (EN) (566.57 KB - DOCX)

**First published:** 19/09/2025

[View](/en/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-181)

български (BG) (600.13 KB - DOCX)

**First published:**

19/09/2025

[View](/bg/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_bg.docx)

español (ES) (587.71 KB - DOCX)

**First published:**

19/09/2025

[View](/es/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_es.docx)

čeština (CS) (585.85 KB - DOCX)

**First published:**

19/09/2025

[View](/cs/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (577.41 KB - DOCX)

**First published:**

19/09/2025

[View](/da/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (581.04 KB - DOCX)

**First published:**

19/09/2025

[View](/de/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (573.29 KB - DOCX)

**First published:**

19/09/2025

[View](/et/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (571.88 KB - DOCX)

**First published:**

19/09/2025

[View](/el/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_el.docx)

français (FR) (591.81 KB - DOCX)

**First published:**

19/09/2025

[View](/fr/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (563.84 KB - DOCX)

**First published:**

19/09/2025

[View](/hr/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (579.27 KB - DOCX)

**First published:**

19/09/2025

[View](/is/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_is.docx)

italiano (IT) (589.18 KB - DOCX)

**First published:**

19/09/2025

[View](/it/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (561.41 KB - DOCX)

**First published:**

19/09/2025

[View](/lv/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (570.08 KB - DOCX)

**First published:**

19/09/2025

[View](/lt/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (580.48 KB - DOCX)

**First published:**

19/09/2025

[View](/hu/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (587.45 KB - DOCX)

**First published:**

19/09/2025

[View](/mt/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (564.67 KB - DOCX)

**First published:**

19/09/2025

[View](/nl/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (571.38 KB - DOCX)

**First published:**

19/09/2025

[View](/no/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_no.docx)

polski (PL) (581.69 KB - DOCX)

**First published:**

19/09/2025

[View](/pl/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_pl.docx)

português (PT) (592.89 KB - DOCX)

**First published:**

19/09/2025

[View](/pt/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_pt.docx)

română (RO) (586.76 KB - DOCX)

**First published:**

19/09/2025

[View](/ro/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (864.93 KB - DOCX)

**First published:**

19/09/2025

[View](/sk/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (567.19 KB - DOCX)

**First published:**

19/09/2025

[View](/sl/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (618.82 KB - DOCX)

**First published:**

19/09/2025

[View](/fi/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (566.97 KB - DOCX)

**First published:**

19/09/2025

[View](/sv/documents/product-information-tracked-changes/jubbonti-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 27/11/2025

## Share this page

[Back to top](#main-content)